Enzyme Engineering

& Industrial Fermentation

Enzymes are widely used as biocatalysts in the production or processing of a wide range of products including food, beverages, animal feeds, detergents, pharmaceuticals and textile products. Naturally occurring enzymes are often unstable or perform sub-optimally when moved from the biological to the industrial sphere.

Therefore, since the advent of protein engineering there have been efforts to improve these enzyme properties, and even to devise enzymes with novel specificities capable of producing types or quantities of metabolites not normally achievable in natural products. Such improvements or changes can often be challenging: enzyme activity depends on specific and highly complex structures, sometimes formed from multiple protein components, and requiring associated factors or metal ions to operate. Frequently, enhancing one desirable property comes at the cost of impairing another.

Mewburn Ellis has a long history of working with our clients in this fast-moving and competitive field. For example, we’ve been involved in protecting the ground-breaking innovations on the serine protease subtilisin (used for example in detergents and in food processing) since 1980s, and in multiple other enzymes in different fields such as brewing, biofuels and biopolymers. The Mewburn team has regularly and successfully defended patents covering our clients’ enzyme technologies at the EPO and assisted them in enforcing those patents before national courts. Engineered enzymes are typically produced in host species such as bacteria, yeasts and filamentous fungi and we also have many years’ experience in dealing with the fermentation technologies used for growing these microorganisms, and recovering the enzymes from them, whether at laboratory or industrial scale.

As more and more powerful computation tools are developed for determining and modelling protein structures, so protein engineers are increasingly able to analyse the structure-function characteristics for rationale design of novel enzymes, which can then be tested in large scale functional screening processes. Once again, our specialised team here is able to assist at our clients with obtaining protection for their intellectual property in the latest bioinformatics innovations in the enzyme space.

Open pages of Green IP Report

Green IP Report

Patents are both a driver and a barometer of innovation

Our report examines the role of patents in making innovative ‘green’ technologies into a reality as well as how the patent landscape can be used to identify opportunities for partnering, collaboration and investment.

We share our enthusiasm and admiration for commercially-focused innovation across a diverse range of technologies, from repurposing carbon dioxide to make protein-rich foods, to the multi-faceted approach to a circular plastics economy. We also discuss the tantalising prospect of AI-mediated renewable energy supply, and the harnessing of battery tech from the EV boom to drive energy efficiency in consumer devices. This report reflects our passion for technology solutions that tackle our shared global challenge.

Download the Report

Read our Blogs

What the EU’s New Genomic Techniques (NGT) Regulation Means for Plant Innovators

What the EU’s New Genomic Techniques (NGT) Regulation Means for Plant Innovators

by Louise Atkins

This week, the European Parliament will cast its final vote on the EU’s new regulatory framework for plants developed using New Genomic Techniques (NGTs). This vote follows the provisional agreement ...

BioTryp’s radical new treatment for bacterial infection

BioTryp’s radical new treatment for bacterial infection

by Louise Atkins

Cambridge University spin-out BioTryp is developing inhibitors that disrupt a signalling mechanism of bacteria to prevent the formation of biofilms, thereby reducing infection. Forward: features are ...

We are a leading force in EPO oppositions

We are a leading force in EPO oppositions

by Alex Galbraith

When it comes to opposing or defending European patents, experience matters. A look at our track record across both offensive and defensive oppositions over the last 12 years highlights not only the ...

UPC Weekly - Three darts all miss – PI based on three patents refused due to validity concerns and insufficient proof of infringement

UPC Weekly - Three darts all miss – PI based on three patents refused due to validity concerns and insufficient proof of infringement

by Eliot Ward

2026 Week 5 For good or bad, it is now clear that inter partes preliminary injunction (PI) proceedings at the UPC end up being mini-trials of the substantive issues. In Guardant Health v. Sophia ...

Round up of recent EPO Board of Appeal decisions relating to antibodies

Round up of recent EPO Board of Appeal decisions relating to antibodies

by Joanna Cripps

We have carried out our annual review of EPO Board of Appeal decisions published up to the end of 2025 where the claimed subject matter relates to antibodies. We have selected those decisions that ...

Most opposed patents of 2025

Most opposed patents of 2025

by Katherine Green

Writing this year’s overview prompted déjà vu and a quick check of 2024’s most opposed patents confirmed that the same innovators feature at the top of the list: patents in the name of Novartis (for ...

Learn More
ME Forward Masthead White 2